|
Total number of patients
|
52
|
|
Age, years (mean ± SD)
|
71.5 ± 9
|
|
PSA at first PET/CT (ng/ml), median (IQR)
|
6.6 (1.3–28.3)
|
|
PSA at second PET/CT (ng/ml), median (IQR)
|
1.6 (0.3–12.1)
|
|
Gleason score (n)
|
|
6
|
6 (11.5%)
|
|
7
|
2 (3.8%)
|
|
7 (3 + 4)
|
8 (15.4%)
|
|
7 (4 + 3)
|
6 (11.5%)
|
|
8
|
9 (17.3%)
|
|
9
|
12 (23.1%)
|
|
10
|
2 (3.8%)
|
|
n/a
|
7 (13.5%)
|
|
Disease extent demonstrated on first PET/CT (n)
|
|
Prostatic disease
|
29 (55.8%)
|
|
Bone metastases
|
32 (61.5%)
|
|
Lymph nodes
|
42 (80.8%)
|
|
Liver metastases
|
2 (3.8%)
|
|
Peritoneal implants
|
2 (3.8%)
|
|
Lung metastases
|
1 (1.9%)
|
|
Treatment received between the two PET/CT scans (n)
|
|
Hormonal therapy
|
42 (80.8%)
|
|
Salvage radiotherapy
|
17 (32.7%)
|
|
Chemotherapy
|
12 (23.1%)
|
|
Radium-223
|
2 (3.8%)
|
